Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab vs placebo in moderately to severely active Crohn's disease
CTR20200092Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mirikizumab in Crohn's disease, sponsored by Eli Lilly and Company. Started Apr 2020; status: completed.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20200092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200092.